drugset / Trial / NCT01456689

A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma

NCT01456689

Phase 1 Completed 79 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary purpose of this dose escalation study is to estimate the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) of LGH447 as a single agent when administered orally once daily to adult patients with Multiple Myeloma (MM).

Timeline

Start
2012-04-25
Primary completion
2019-06-05
Completion
2019-06-05

Drugs

EvaluationDrugModalityDoseRoute
Subject LGH447 Small molecule Oral
Subject Midazolam Small molecule

Indications